Creative Planning Acquires 8,993 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

Creative Planning boosted its holdings in shares of TG Therapeutics, Inc. (NASDAQ:TGTX) by 19.2% during the 3rd quarter, Holdings Channel reports. The firm owned 55,832 shares of the biopharmaceutical company’s stock after buying an additional 8,993 shares during the period. Creative Planning’s holdings in TG Therapeutics were worth $1,306,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new stake in TG Therapeutics during the 2nd quarter valued at approximately $35,000. ORG Wealth Partners LLC bought a new stake in TG Therapeutics in the 3rd quarter worth approximately $53,000. DekaBank Deutsche Girozentrale bought a new stake in TG Therapeutics in the 1st quarter worth approximately $58,000. nVerses Capital LLC increased its stake in TG Therapeutics by 34.9% in the 2nd quarter. nVerses Capital LLC now owns 5,800 shares of the biopharmaceutical company’s stock worth $103,000 after acquiring an additional 1,500 shares during the last quarter. Finally, Quarry LP increased its stake in TG Therapeutics by 9.1% in the 2nd quarter. Quarry LP now owns 6,003 shares of the biopharmaceutical company’s stock worth $107,000 after acquiring an additional 503 shares during the last quarter. Institutional investors own 58.58% of the company’s stock.

TG Therapeutics Price Performance

Shares of TGTX stock opened at $25.13 on Thursday. TG Therapeutics, Inc. has a twelve month low of $7.17 and a twelve month high of $26.41. The stock has a market capitalization of $3.88 billion, a price-to-earnings ratio of 109.26 and a beta of 2.21. The stock has a fifty day simple moving average of $23.44 and a two-hundred day simple moving average of $19.89. The company has a current ratio of 3.58, a quick ratio of 2.83 and a debt-to-equity ratio of 0.58.

TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.04 earnings per share for the quarter, topping the consensus estimate of ($0.04) by $0.08. The business had revenue of $73.47 million during the quarter, compared to analysts’ expectations of $65.92 million. TG Therapeutics had a return on equity of 57.73% and a net margin of 27.60%. The business’s revenue for the quarter was up 357.0% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.34) EPS. On average, analysts predict that TG Therapeutics, Inc. will post 0.13 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of research firms have issued reports on TGTX. TD Cowen assumed coverage on TG Therapeutics in a research note on Tuesday. They issued a “buy” rating and a $50.00 price objective on the stock. HC Wainwright restated a “buy” rating and set a $49.00 price objective on shares of TG Therapeutics in a report on Wednesday, September 18th. B. Riley boosted their price objective on TG Therapeutics from $29.00 to $34.00 and gave the company a “buy” rating in a report on Wednesday, August 7th. Finally, The Goldman Sachs Group boosted their price objective on TG Therapeutics from $18.00 to $20.00 and gave the company a “neutral” rating in a report on Wednesday, August 7th. Two investment analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. According to data from MarketBeat, TG Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $34.43.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.